Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:9/10/2007

ive cancer treatment. We at CEL-SCI share that view.

A review of the successes and failures of the past indicates that the current products on the market or in development that attempt to utilize the immune system to rid the body of cancer have the following draw backs:

1) They are given to patients after the patient has received

chemotherapy, radiation or surgery. This is most often too late!!!

At that point the patient's immune system is so damaged from the

patient's cancer and the cancer therapy that it can no longer mount

an effective anti-tumor immune response.

2) They are targeted to a specific antigen on a tumor and attack that

tumor only in one way. There are many antigens that need to be

attacked to overcome the very complex tumor defense mechanisms and

the constant mutation of the tumor antigens cannot be addressed with

a 'one key fits all' approach.

3) They act like specific parts of our immune system, when in reality

we need a more complete immune approach (the whole army vs.

specialized soldiers only).

Cancer is a very complex disease and requires a comprehensive immune system approach. Our Multikine is designed to address the shortfalls outlined above and provide a comprehensive anti-tumor immune response that most closely resembles the workings of the natural immune system. It is comprehensive in the sense that it works on multiple fronts in the battle against cancer, and it is toxic only to cancer cells.

Multikine represents a new class of immunotherapy drugs, Immune SIMULATORS, since it simulates a healthy immune response. It works 1) because it is given prior to the first cancer treatment, before the immune system is weakened by standard cancer therapies, and 2) because it attacks the tumor on multiple fronts (multi-targeted), not only one front.

Multikine is multi-targeted because:

1) It acts on multiple targe
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
2. CEL-SCI Presents Long-Term Cancer Survival Data With Multikine
3. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
4. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
5. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
6. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
7. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
8. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
9. Insmed Releases Positive Results from Iplex Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
10. State of Diabetes in Pittsburgh: Pittsburgh Business Group on Health Releases Report
11. Bipolar Disorder in Children Difficult to Diagnose, Reports the Harvard Mental Health Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015 ... Report on Global Azithromycin Industry and 2015 ... Industry reports added to Pharmaceutical category in ... the report introduces Azithromycin basic information, including ... overview, policy analysis, and news analysis, etc. ...
(Date:4/1/2015)... 1, 2015  Boston Scientific Corporation (NYSE: BSX ) ... at 8 a.m. ET to review financial results and business ... a news release announcing first quarter financial results prior to ... by Mike Mahoney , president and chief executive officer, ... financial officer. A live webcast of the conference ...
(Date:4/1/2015)... Mar. 30, 2015 Research and Markets ... of the "Medical Device Studies: Clinical Evidence" ... course has been designed specifically for those who ... medical devices and in-vitro diagnostic products. Clinical data ... emphasis on high quality, appropriate clinical evidence has ...
Breaking Medicine Technology:Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 2Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 3Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 4Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 5Boston Scientific To Webcast Conference Call On First Quarter 2015 Financial Results 2Medical Device Studies: Clinical Evidence Seminar - London, UK, 13th, 14th of May 2015 2
... Inc. (NYSE: MTD ) today announced the webcast ... in New York on Wednesday, September 21, 2011, at 9:00 ... presentation, visit the investor relations page on the Company,s Web ... will be available for seven days. METTLER TOLEDO ...
... JERUSALEM, Sept. 14, 2011 Chiasma, Inc., a privately held ... will present an overview of the Company at the UBS ... New York, on Monday, September 19, 2011 at 1:30 PM. ... form of octreotide acetate being developed first for the oral ...
Cached Medicine Technology:Chiasma to Present at the UBS Global Life Sciences Conference 2
(Date:4/1/2015)... Dr. Daniel C. Stewart will be ... the benefits of the LANAP® treatment over traditional ... People who live in Howard County, and surrounding areas ... visit Dr. Stewart, a Maryland dentist, for a minimally ... protocol, which is a laser gum surgery procedure, Dr. ...
(Date:4/1/2015)... Ill. (PRWEB) April 01, 2015 OSF ... OSF Healthcare System , was welcomed into the ... Ceremony officiated by Msgr. Paul E. Showalter, vicar general ... The Blessing and Dedication culminated a nearly year-long transition ... eleventh OSF HealthCare hospital. Speakers for the morning ceremony ...
(Date:4/1/2015)... 01, 2015 Aging2.0 , the ... announces the launch of the Aging2.0 Alliance ... stakeholders and technology companies. The announcement was made today ... and Business Strategies Forum in San Diego, CA. ... Alliance program is now open for additional members. “This ...
(Date:4/1/2015)... April 01, 2015 Dr. Rod ... Distinguished Teaching Professor of the Department of Plastic Surgery ... doctors to review reports of blindness resulting from the ... . The group published their study, along with ideas ... Surgery journal. , "We began to see increasing reports ...
(Date:4/1/2015)... EB Medicine, leading publisher of ... Practice, and Hospital Medicine Practice, is pleased to ... provide the content from its flagship publication, ... format available on iPhones, iPads and Android smartphones ... to develop mobile applications for EB Medicine’s journals ...
Breaking Medicine News(10 mins):Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 2Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 3Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 2Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 2Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 4Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 2Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 3Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 2Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 3
... , ... Fresh Look at Coping with Multiple Sclerosis through Community , ... (PRWEB) April 13, 2010 -- Motivational Speaker/MS ... guidebook for those newly diagnosed with Multiple Sclerosis. , , ,Published by iUniverse ...
... likely to develop, die from disease , TUESDAY, April 13 ... comes to both developing and dying from lung cancer. , ... grim picture of how environmental factors, biological factors, cultural attitudes ... deadly disease even deadlier among members of this minority group. ...
... ... patients and may be covered by medical insurance will be provided by Khanna institute in ... (Vocus) April ... with countless solutions for eye and sight problems, hereby announces that it is offering its ...
... mutated gene in human cancers is the reitnoblastoma (RB) gene, ... gene disable the vast and intricate RB pathway in virtually ... cellular functions and ultimately provoking cancer. But which of these ... uncertain. "We have now found that a key function ...
... ... general availability of ActiveStrategy iRound™, which enables field-level performance management data to be ... Enterprise software. , ... (PRWEB) April 13, 2010 -- ActiveStrategy, the leading provider of comprehensive ...
... on failure rates could aid surgeons who import donor tissue, ... a corneal transplant will fail is not affected by the ... transplanted cornea was preserved or the method of preservation, according ... study that included 388 people who were followed for up ...
Cached Medicine News:Health News:Author Erin Morrow Still Releases "Fighting MS: Strength in Numbers" 2Health News:Author Erin Morrow Still Releases "Fighting MS: Strength in Numbers" 3Health News:Blacks Hit Hardest by Lung Cancer 2Health News:Blacks Hit Hardest by Lung Cancer 3Health News:Khanna Institute to Provide Intacs Corneal Implants in Beverly Hills 2Health News:Khanna Institute to Provide Intacs Corneal Implants in Beverly Hills 3Health News:CSHL scientists discover how a tumor suppressor induces senescence and staves off cancer 2Health News:ActiveStrategy iRound™ is Launched to Enable Seamless Capture of Field-Level Performance Management Data 2Health News:ActiveStrategy iRound™ is Launched to Enable Seamless Capture of Field-Level Performance Management Data 3Health News:Corneal Transplant Not Hurt by Long Preservation Time 2
Straight 20 mm serrated jaws. Ring handle with ratchet lock and dull finish. Overall length 3.9 inches...
Curved 21 mm serrated jaws. Ring handle with ratchet lock. Non-magnetic and dull finish. Overall length 4.7 inches....
Angled 55 degree shafts with 9.5 mm tips. Tongue and groove platform for tying sutures and grasping silicone bonding and buckling material. Serrated handle with polished finish....
Straight shafts with fitted v-grooved 15 mm platform. Serrated handle with polished finish....
Medicine Products: